Preclinical Development of the Live, Single-Cycle, Next-Generation SARS-CoV-2 Vaccine (RVX-13) - Texts

Home
Main Navigation
Content
Search
Help

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

52533.1 IP-LS

Project title

Preclinical Development of the Live, Single-Cycle, Next-Generation SARS-CoV-2 Vaccine (RVX-13)

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract		-	-	-

Inserted texts

Category	Text
Short description (German)	Preclinical Development of the Live, Single-Cycle, Next-Generation SARS-CoV-2 Vaccine (RVX-13)
Short description (English)	Preclinical Development of the Live, Single-Cycle, Next-Generation SARS-CoV-2 Vaccine (RVX-13)
Abstract (German)	RocketVax AG, a startup company from Basel, together with academic partners in Switzerland, will develop a next-generation vaccine against SARS-CoV-2. Based on a live, single-cycle virus, this vaccine will provide a broader and more durable protection, offering a superior and long-term solution.